Advisory Commission on Childhood Vaccines; Notice of Meeting, 70169-70170 [2012-28377]
Download as PDF
Federal Register / Vol. 77, No. 226 / Friday, November 23, 2012 / Notices
Applications for Artificial Pancreas
Device Systems,’’ you may either send
an email request to dsmica@fda.hhs.gov
to receive an electronic copy of the
document or send a fax request to 301–
847–8149 to receive a hard copy. Please
use the document number 1759 to
identify the guidance you are
requesting.
IV. Paperwork Reduction Act
This guidance refers to currently
approved collections of information
found in FDA regulations and guidance
documents. These collection of
information are subject to review by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3520). The
collections of information in 21 CFR
54.4 are approved under OMB control
number 0910–0396; the collections of
information in 21 CFR 56.115 are
approved under OMB control number
0910–0130; the collections of
information in 21 CFR parts 801 and
809 are approved under OMB control
number 0910–0485; the collections of
information in 21 CFR part 812 are
approved under OMB control number
0910–0078; and the collections of
information in 21 CFR part 814 are
approved under OMB control number
0910–0231; the collections of
information in 21 CFR part 820 are
approved under OMB control number
0910–0073.
V. Comments
Interested persons may submit either
written comments regarding this
document to the Division of Dockets
Management (see ADDRESSES) or
electronic comments to https://
www.regulations.gov. It is only
necessary to send one set of comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
mstockstill on DSK4VPTVN1PROD with NOTICES
Dated: November 16, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–28339 Filed 11–21–12; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
17:03 Nov 21, 2012
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
Advisory Committee on
Interdisciplinary, Community-Based
Linkages; Notice of Meeting
In accordance with section 10(a)(2) of the
Federal Advisory Committee Act (Pub. L. 92–
463), notice is hereby given of the following
meeting:
Name: Advisory Committee on
Interdisciplinary, Community-Based
Linkages (ACICBL).
Dates and Times: December 7, 2012,
1:00 p.m.–5:00 p.m. EST.
Place: Webinar and Conference Call
Format.
SUPPLEMENTARY INFORMATION: Status:
The meeting will be open to the public.
The conference call access will be
limited only by availability of telephone
ports.
Purpose: The members of the ACICBL
will begin the planning required to
develop the legislatively mandated 13th
Annual Report to the Secretary of
Health and Human Services and
Congress. The meeting objectives are to:
(1) Focus on a relevant topic that will
enhance the mission of the Title VII
training programs; (2) develop an
outline that will inform the
development of the 13th Annual Report;
(3) provide an update on training
programs; and (4) provide an update on
the 12th Annual Report.
Agenda: The ACICBL agenda includes
an opportunity for each member to offer
ideas for the upcoming report, along
with identifying consultants in specific
areas who could provide expert
testimony. The staff writer provided by
the Health Resources and Services
Administration (HRSA), Bureau of
Health Professions, will offer a strategy
for outlining the upcoming report. The
agenda will be available days prior to
the meeting on the HRSA Web site
(https://www.hrsa.gov/advisory
committees/bhpradvisory/acicbl/
acicbl.html). Agenda items are subject to
change as priorities dictate.
Individuals who plan to participate
on the webinar should register at least
one day prior to the meeting, using the
following webinar information: https://
hrsa.connectsolutions.com/
r5x1ckkknl6. The conference call-in
number is 1–800–857–5750, using the
participant passcode 6694174.
Requests to make oral comments or
provide written comments to the
ACICBL should be sent to Dr. Joan
Weiss, Designated Federal Official, at
least 3 days prior to the meeting using
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
70169
the address and phone number below.
Individuals who plan to participate on
the conference call or webinar should
notify Dr. Weiss at least 3 days prior to
the meeting, using the address and
phone number below. Members of the
public will have the opportunity to
provide comments. Interested parties
should refer to meeting subject as the
HRSA Advisory Committee on
Interdisciplinary, Community-Based
Linkages.
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
regarding the ACICBL should contact
Dr. Joan Weiss, Designated Federal
Official within the Bureau of Health
Professions, Health Resources and
Services Administration, in one of three
ways: (1) Send a request to the following
address: Dr. Joan Weiss, Designated
Federal Official, Bureau of Health
Professions, Health Resources and
Services Administration, Parklawn
Building, Room 9C–05, 5600 Fishers
Lane, Rockville, Maryland 20857; (2)
call (301) 443–6950; or (3) email
jweiss@hrsa.gov. The web address for
information on the Advisory Committee
is https://www.hrsa.gov/advisory
committees/bhpradvisory/acicbl/
acicbl.html.
Dated: November 16, 2012.
Bahar Niakan,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2012–28378 Filed 11–21–12; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Commission on Childhood
Vaccines; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: Advisory Commission on
Childhood Vaccines (ACCV).
Date and Time: December 6, 2012, 1:00
p.m. to 4:45 p.m. EDT.
Place: Parklawn Building (and via audio
conference call), 5600 Fishers Lane,
Conference Room 10–65, Rockville, MD
20857.
The ACCV will meet on Thursday,
December 6, 2012, from 1:00 p.m. to 4:45
p.m. (EDT). The public can join the meeting
via audio conference call by dialing 1–800–
369–3104 on December 6 and providing the
following information:
Leader’s Name: Dr. Vito Caserta.
Password: ACCV.
E:\FR\FM\23NON1.SGM
23NON1
70170
Federal Register / Vol. 77, No. 226 / Friday, November 23, 2012 / Notices
Agenda: The agenda items for the
December meeting will include, but are not
limited to: updates from the Division of
Vaccine Injury Compensation (DVIC);
Department of Justice (DOJ); National
Vaccine Program Office (NVPO);
Immunization Safety Office (Centers for
Disease Control and Prevention); National
Institute of Allergy and Infectious Diseases
(National Institutes of Health); and Center for
Biologics, Evaluation and Research (Food
and Drug Administration). A draft agenda
and additional meeting materials will be
posted on the ACCV Web site (https://www.
hrsa.gov/vaccinecompensation/accv.htm)
prior to the meeting. Agenda items are
subject to change as priorities dictate.
Public Comment: Persons interested in
attending the meeting in person or providing
an oral presentation should submit a written
request along with a copy of their
presentation to: Annie Herzog, DVIC,
Healthcare Systems Bureau (HSB), Health
Resources and Services Administration
(HRSA), Room 11C–26, 5600 Fishers Lane,
Rockville, Maryland 20857 or email:
aherzog@hrsa.gov. Requests should contain
the name, address, telephone number, email
address, and any business or professional
affiliation of the person desiring to make an
oral presentation. Groups having similar
interests are requested to combine their
comments and present them through a single
representative. The allocation of time may be
adjusted to accommodate the level of
expressed interest. DVIC will notify each
presenter by email, mail, or telephone of
their assigned presentation time. Persons
who do not file an advance request for a
presentation, but desire to make an oral
statement, may announce it at the time of the
public comment period. Public participation
and ability to comment will be limited to
space and time as it permits.
For Further Information Contact: Anyone
requiring information regarding the ACCV
should contact Annie Herzog, DVIC, HSB,
HRSA, Room 11C–26, 5600 Fishers Lane,
Rockville, MD 20857; telephone (301) 443–
6593; or email: aherzog@hrsa.gov.
Dated: November 16, 2012.
Bahar Niakan,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2012–28377 Filed 11–21–12; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel,
December 3, 2012, 8:30 a.m. to
December 4, 2012, 5:00 p.m., which was
published in the Federal Register on
November 1, 2012, 77 FR Pg. 66854–
66855.
VerDate Mar<15>2010
17:03 Nov 21, 2012
Jkt 229001
The meeting will be held November
27–28, 2012 at 8:30 a.m. and will end
at 5:00 p.m. The meeting location
remains the same. The meeting is closed
to the public.
Dated: November 16, 2012
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–28368 Filed 11–21–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Experimental Therapeutics Program (NExT).
Date: December 12, 2012.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health,
Neuroscience Building, 6001 Executive
Boulevard, Conference Room A1 & A2,
Bethesda, MD 20852.
Contact Person: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20892,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Joseph Tomaszewski, Ph.D., Executive
Secretary, Development Experimental
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44,
Bethesda, MD 20892, (301) 496–6711,
tomaszej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 16, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–28370 Filed 11–21–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel NCI
Experimental Therapeutics Program (NExT).
Date: December 12, 2012.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health,
Neuroscience Building, 6001 Executive
E:\FR\FM\23NON1.SGM
23NON1
Agencies
[Federal Register Volume 77, Number 226 (Friday, November 23, 2012)]
[Notices]
[Pages 70169-70170]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28377]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Commission on Childhood Vaccines; Notice of Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), notice is hereby given of the following
meeting:
Name: Advisory Commission on Childhood Vaccines (ACCV).
Date and Time: December 6, 2012, 1:00 p.m. to 4:45 p.m. EDT.
Place: Parklawn Building (and via audio conference call), 5600
Fishers Lane, Conference Room 10-65, Rockville, MD 20857.
The ACCV will meet on Thursday, December 6, 2012, from 1:00 p.m.
to 4:45 p.m. (EDT). The public can join the meeting via audio
conference call by dialing 1-800-369-3104 on December 6 and
providing the following information:
Leader's Name: Dr. Vito Caserta.
Password: ACCV.
[[Page 70170]]
Agenda: The agenda items for the December meeting will include,
but are not limited to: updates from the Division of Vaccine Injury
Compensation (DVIC); Department of Justice (DOJ); National Vaccine
Program Office (NVPO); Immunization Safety Office (Centers for
Disease Control and Prevention); National Institute of Allergy and
Infectious Diseases (National Institutes of Health); and Center for
Biologics, Evaluation and Research (Food and Drug Administration). A
draft agenda and additional meeting materials will be posted on the
ACCV Web site (https://www.hrsa.gov/vaccinecompensation/accv.htm)
prior to the meeting. Agenda items are subject to change as
priorities dictate.
Public Comment: Persons interested in attending the meeting in
person or providing an oral presentation should submit a written
request along with a copy of their presentation to: Annie Herzog,
DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services
Administration (HRSA), Room 11C-26, 5600 Fishers Lane, Rockville,
Maryland 20857 or email: aherzog@hrsa.gov. Requests should contain
the name, address, telephone number, email address, and any business
or professional affiliation of the person desiring to make an oral
presentation. Groups having similar interests are requested to
combine their comments and present them through a single
representative. The allocation of time may be adjusted to
accommodate the level of expressed interest. DVIC will notify each
presenter by email, mail, or telephone of their assigned
presentation time. Persons who do not file an advance request for a
presentation, but desire to make an oral statement, may announce it
at the time of the public comment period. Public participation and
ability to comment will be limited to space and time as it permits.
For Further Information Contact: Anyone requiring information
regarding the ACCV should contact Annie Herzog, DVIC, HSB, HRSA,
Room 11C-26, 5600 Fishers Lane, Rockville, MD 20857; telephone (301)
443-6593; or email: aherzog@hrsa.gov.
Dated: November 16, 2012.
Bahar Niakan,
Director, Division of Policy and Information Coordination.
[FR Doc. 2012-28377 Filed 11-21-12; 8:45 am]
BILLING CODE 4165-15-P